Amgen Files NDA, Seeks FDA Approval For Parathyroid Drug
August 25, 2015 at 20:49 PM EDT
Amgen shares end the day down 1% after filing an NDA for its intravenous drug etelcalcetide.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.